NO20073813L - Kladribinregime for behandling av multippel sklerose - Google Patents

Kladribinregime for behandling av multippel sklerose

Info

Publication number
NO20073813L
NO20073813L NO20073813A NO20073813A NO20073813L NO 20073813 L NO20073813 L NO 20073813L NO 20073813 A NO20073813 A NO 20073813A NO 20073813 A NO20073813 A NO 20073813A NO 20073813 L NO20073813 L NO 20073813L
Authority
NO
Norway
Prior art keywords
multiple sclerosis
treatment
cladribine
regimen
cladribine regimen
Prior art date
Application number
NO20073813A
Other languages
English (en)
Norwegian (no)
Inventor
Giampiero De Luca
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20073813(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Serono Lab filed Critical Serono Lab
Publication of NO20073813L publication Critical patent/NO20073813L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NO20073813A 2004-12-22 2007-07-20 Kladribinregime for behandling av multippel sklerose NO20073813L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22
PCT/EP2005/056954 WO2006067141A1 (fr) 2004-12-22 2005-12-20 Schema posologique a base de cladribine destine a traiter la sclerose en plaques

Publications (1)

Publication Number Publication Date
NO20073813L true NO20073813L (no) 2007-09-21

Family

ID=36227798

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073813A NO20073813L (no) 2004-12-22 2007-07-20 Kladribinregime for behandling av multippel sklerose

Country Status (25)

Country Link
US (2) US7713947B2 (fr)
EP (7) EP2275110B1 (fr)
JP (7) JP5795456B2 (fr)
KR (1) KR20070091662A (fr)
AR (1) AR052830A1 (fr)
AU (2) AU2005318190B2 (fr)
BR (1) BRPI0517132B8 (fr)
CA (2) CA2588966C (fr)
CY (3) CY1112614T1 (fr)
DK (3) DK2805723T3 (fr)
EA (1) EA015799B1 (fr)
ES (2) ES2921858T3 (fr)
FI (1) FI4070800T3 (fr)
FR (1) FR18C1008I2 (fr)
HR (1) HRP20120228T1 (fr)
HU (3) HUE070333T2 (fr)
IL (2) IL183930A0 (fr)
LT (3) LT4070800T (fr)
LU (1) LUC00064I2 (fr)
MX (1) MX2007007610A (fr)
NO (1) NO20073813L (fr)
PL (4) PL2805723T3 (fr)
SG (1) SG160391A1 (fr)
SI (3) SI3332789T1 (fr)
WO (1) WO2006067141A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2805723T3 (da) 2004-12-22 2018-01-29 Merck Serono Sa Cladribin-regime til behandling af multipel sclerose
MX2008014971A (es) 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.
EP2343074A1 (fr) 2009-12-23 2011-07-13 Merck Serono S.A. Utilisation d'analogues de la purine pour traiter des maladies des voies respiratoires
WO2011117267A1 (fr) 2010-03-24 2011-09-29 Merck Serono Sa Traitement à la cladribine de la sclérose en plaques chez des groupes de patients définis par génotype
EP2428201A1 (fr) 2010-09-08 2012-03-14 Merck Serono S.A. Administration orale de nucléosides monophosphates
WO2012097867A1 (fr) 2011-01-18 2012-07-26 Synthon Bv Particules de cladribine et compositions pharmaceutiques comprenant celles-ci
GB201401465D0 (en) 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) * 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
CN111356460A (zh) * 2017-11-24 2020-06-30 默克专利股份公司 用于治疗进展型形式的多发性硬化症的克拉屈滨疗法
CA3194812A1 (fr) 2020-09-10 2022-03-17 Merck Patent Gmbh Nouveau regime de traitement pour le traitement de troubles auto-immuns
GB2601786A (en) * 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (fr) 1984-08-06 1990-05-29 Brigham Young University Preparation de composes a base de 2'-desoxyadenosine
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
PT801571E (pt) 1994-12-22 2002-12-31 Ortho Pharma Corp Formulacoes soluveis de 2-cloro-2'-desoxiadenosina
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (fr) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. Procede de production de 2-chloro-2'-desoxyadenosine (cladribine) et son derive 3,5-di-o-p-toluoyle
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
WO2004028462A2 (fr) 2002-09-25 2004-04-08 Brigham Young University, Technology Transfer Office Procede de preparation de composes de 2-halo-2'-deoxyadenosine a partir de 2'-deoxyguanosine
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
WO2004075903A1 (fr) * 2003-02-25 2004-09-10 Applied Research Systems Ars Holding N.V. Utilisation combinee de ribavirine et d'interferon beta dans des maladies caracterisees par une demyelinisation
KR101129816B1 (ko) 2003-03-28 2012-03-26 아레스 트레이딩 에스.아. 클라드리빈의 경구용 제형
KR20060011943A (ko) 2003-03-28 2006-02-06 아이박스 코포레이션 향상된 경구 및 경점막 수송용 클라드리빈 제형
DK2805723T3 (da) 2004-12-22 2018-01-29 Merck Serono Sa Cladribin-regime til behandling af multipel sclerose
MX2008014971A (es) * 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.

Also Published As

Publication number Publication date
HUE059133T2 (hu) 2022-10-28
HUE070333T2 (hu) 2025-05-28
JP5795456B2 (ja) 2015-10-14
JP2008524313A (ja) 2008-07-10
FR18C1008I1 (fr) 2018-03-30
PL4070800T3 (pl) 2025-03-10
JP6092945B2 (ja) 2017-03-08
EP4070800A1 (fr) 2022-10-12
PL1827461T3 (pl) 2012-07-31
KR20070091662A (ko) 2007-09-11
EP3332789B1 (fr) 2022-04-06
BRPI0517132B1 (pt) 2020-02-18
EP2263678B1 (fr) 2014-06-11
DK2805723T3 (da) 2018-01-29
EP2263678A2 (fr) 2010-12-22
EP2805723B1 (fr) 2018-01-17
AU2005318190B2 (en) 2010-11-25
HRP20120228T1 (hr) 2012-04-30
LTPA2018503I1 (lt) 2018-03-12
SI3332789T1 (sl) 2022-08-31
EP4523753A2 (fr) 2025-03-19
LTC2805723I2 (lt) 2022-04-25
BRPI0517132A (pt) 2008-09-30
IL212421A0 (en) 2011-06-30
EP2275110A3 (fr) 2011-04-27
AU2005318190A1 (en) 2006-06-29
EP4070800B1 (fr) 2024-10-16
JP5908863B2 (ja) 2016-04-26
CY2018006I2 (el) 2018-06-27
JP2018165271A (ja) 2018-10-25
CA3087419C (fr) 2023-03-07
JP2017101061A (ja) 2017-06-08
EP2275110A2 (fr) 2011-01-19
CA2588966A1 (fr) 2006-06-29
AU2011200768B2 (en) 2012-09-13
JP6430554B2 (ja) 2018-11-28
CY1119790T1 (el) 2018-06-27
LUC00064I1 (fr) 2018-02-14
CA2588966C (fr) 2020-07-21
FR18C1008I2 (fr) 2019-03-01
AR052830A1 (es) 2007-04-04
EP1827461A1 (fr) 2007-09-05
LT4070800T (lt) 2025-01-10
JP2016138128A (ja) 2016-08-04
ES3007339T3 (en) 2025-03-19
SG160391A1 (en) 2010-04-29
US7713947B2 (en) 2010-05-11
SI4070800T1 (sl) 2025-03-31
LUC00064I2 (fr) 2018-03-28
AU2011200768A1 (en) 2011-03-17
JP2015180685A (ja) 2015-10-15
MX2007007610A (es) 2007-08-03
JP2020193206A (ja) 2020-12-03
EA015799B1 (ru) 2011-12-30
DK3332789T3 (da) 2022-07-11
DK4070800T3 (da) 2025-01-02
PL3332789T3 (pl) 2022-08-22
US20090081163A1 (en) 2009-03-26
IL183930A0 (en) 2007-10-31
CY1112614T1 (el) 2016-02-10
ES2921858T3 (es) 2022-09-01
EP3332789A1 (fr) 2018-06-13
US8377903B2 (en) 2013-02-19
EP2805723A1 (fr) 2014-11-26
BRPI0517132B8 (pt) 2021-05-25
PL2805723T3 (pl) 2018-04-30
CY2018006I1 (el) 2018-06-27
JP6290962B2 (ja) 2018-03-07
EP2263678A3 (fr) 2011-04-27
EP1827461B1 (fr) 2012-02-29
FI4070800T3 (fi) 2025-01-14
LT3332789T (lt) 2022-07-25
US20100203017A1 (en) 2010-08-12
EP4523753A3 (fr) 2025-05-28
CA3087419A1 (fr) 2006-06-29
WO2006067141A1 (fr) 2006-06-29
JP2013216664A (ja) 2013-10-24
SI2805723T1 (en) 2018-02-28
EP2275110B1 (fr) 2013-07-10
HUS1800009I1 (hu) 2018-05-02
EA200701221A1 (ru) 2008-02-28
IL212421A (en) 2014-01-30

Similar Documents

Publication Publication Date Title
NO20073813L (no) Kladribinregime for behandling av multippel sklerose
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
EA200700362A1 (ru) Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью
TW200637614A (en) Bendamustine pharmaceutical compositions
NO20043367L (no) Oralt farmasoytisk preparat
NO20081844L (no) Terapeutiske forbindelser
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
WO2017083304A8 (fr) Compositions thérapeutiques pour le traitement du virus de l'immunodéficience humaine
EA201291089A1 (ru) Способ получения фармацевтических препаратов, предназначенных для перорального введения, содержащих один или более активных ингредиентов, и содержащих их композиций
EA201300420A1 (ru) Комбинации, которые содержат замещенный n-(2-ариламино) арилсульфонамид
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
NO20064078L (no) Substituerte azetidinsammensetninger, deres fremstilling og anvendelse som medikamenter
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
PH12021553056A1 (en) Modified release formulations and uses thereof
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
NO20076405L (no) Anvendelse av 24-nor-UDCA
SE0303480D0 (sv) Benzofuranes
TW200736189A (en) Indene derivatives, their preparation and use as medicaments
UA111480C2 (uk) ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ДЛЯ ЛІКУВАННЯ СИНДРОМУ ПОДРАЗНЕНОГО КИШЕЧНИКУ, ЯКА ВВОДИТЬСЯ ПЕРОРАЛЬНО, ЩО МІСТИТЬ ТРИМЕБУТИН, СИМЕТИКОН, α-D-ГАЛАКТОЗИДАЗУ, І СПОСІБ ЇЇ ОТРИМАННЯ
UA91485C2 (ru) лечебно-профилактическАЯ смесЬ для ухода за полостью рта
JP2009505991A5 (fr)
MX2013012038A (es) Combinacion de carotenoide, fitoestrogeno y vitamina c para la humectacion de la piel.
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application